Figure 2.

PIM kinase inhibitor AZD1208 effect on PIN, proliferation, and apoptosis in prostate grafts. A) Incidence of PIN foci is lower in the AZD1208-treated samples compared with vehicle-treated grafts (χ² P = 1.65x10^-7). B) PIN density measured as number of PIN foci per section is decreased in the AZD1208-treated samples compared with vehicle-treated specimens (χ² P = 3.06x10^-7). N = 88 sections were analyzed for (A) and (B). C) Smooth muscle actin (SMA) immunostaining demonstrates substantial thinning of the SMA-containing boundary around abnormal prostate gland lesions in both the vehicle-treated and AZD1208-treated specimens (arrows). D) BrdU-positive nuclei (arrows) are fewer in AZD1208-treated specimens than controls. E) Increased cleaved caspase-3–positive cells (arrows) in AZD1208-treated specimens than the vehicle-treated specimens. Yellow fluorescent protein (YFP) was used to guide analysis to c-MYC/Pim1-expressing areas in “D” and “E”. F) The percentage of BrdU-positive nuclei is lower in the AZD1208-treated (n = 11) specimens than in the vehicle-treated samples (n = 8) (P = .0016). G) The percentage of cleaved caspase-3–positive cells is greater in the AZD1208-treated (n = 11) specimens than in the vehicle-treated specimens (n = 11) (P = .01 for 30mg/kg, P = .039 for 45mg/kg). Results shown as mean ± SD. *Student’s t test P < .05. #Mann-Whitney rank sum test significance at < .05. Scale bars = 0.05mm.